Tildrakizumab for the treatment of moderate-to-severe psoriasis: a 52-week, real-world Portuguese multicentric study

Tildrakizumab for the treatment of moderate-to-severe psoriasis: a 52-week, real-world Portuguese multicentric study

Background: Real-world evidence plays a pivotal role in validating the efficacy of biologic drugs beyond the controlled environment of randomized trials. This study aimed to evaluate the effectiveness of tildrakizumab in treating moderate-to-severe psoriasis within a real-world setting over a 52-wee...

Full description

Bibliographic Details
Main Authors: Tiago Torres, Paulo Varela, Pedro Mendes Bastos, Sofia Magina, Martinha Henrique, Paulo Ferreira
Format: Article
Language:English
Published: BioExcel Publishing Ltd 2024-03-01
Series:Drugs in Context
Subjects:
biologic
effectiveness
il-23
psoriasis
realworld
safety
tildrakizumab
Online Access:https://www.drugsincontext.com/tildrakizumab-for-the-treatment-of-moderate-to-severe-psoriasis-a-52-week-real-world-portuguese-multicentric-study/

Internet

https://www.drugsincontext.com/tildrakizumab-for-the-treatment-of-moderate-to-severe-psoriasis-a-52-week-real-world-portuguese-multicentric-study/

Similar Items